The best supplements for wet (neovascular) Age-Related Macular Degeneration (AMD) are based on the formulations tested in studies like the Age-Related Eye Disease Study (AREDS) and its follow-up (AREDS2). These supplements can help in slowing the progression of the disease, particularly in individuals with intermediate AMD or those with advanced AMD in one eye¹²:

1. Antioxidants and Zinc: The original AREDS formulation includes high doses of:

   • Vitamin C (500 mg)
   • Vitamin E (400 IU)
   • Beta-Carotene (15 mg, although this is typically avoided in smokers due to increased lung cancer risk)
   • Zinc (80 mg as zinc oxide)
   • Copper (2 mg as cupric oxide to prevent copper deficiency due to high zinc intake)

2. AREDS2 Formulation: This newer formulation modified the original by eliminating beta-carotene and adding lutein and zeaxanthin, along with omega-3 fatty acids in some versions. The recommended doses include:

   • Vitamin C (500 mg)
   • Vitamin E (400 IU or 268 mg)
   • Lutein (10 mg)
   • Zeaxanthin (2 mg)
   • Zinc (25-80 mg)
   • Copper (2 mg for the higher zinc dose)

3. Carotenoids Lutein and Zeaxanthin: These play a critical role due to their antioxidant properties and their ability to filter harmful blue light. They are specifically concentrated in the retina³.

4. B Vitamins: There is emerging evidence that higher intake of certain B vitamins, such as B5, B6, and folate, can reduce the risk of AMD progression⁴.

5. Omega-3 Fatty Acids: Although the addition of omega-3 fatty acids (like DHA and EPA) to the AREDS formulation did not show an additional overall benefit in reducing the risk of progression to late AMD, these supplements are thought to have other health benefits⁵.

These supplements are taken as daily doses and can help reduce the risk of progression of AMD by 25% over five years⁶.

Would you like to search for specific products containing these ingredients?

Footnotes

1. Ângela Carneiro, "Nutritional and Lifestyle Interventions for Age-Related Macular Degeneration: A Review," PubMed Central. ↩

2. Nupura Krishnadev, "Nutritional supplements for age-related macular degeneration," PubMed Central. ↩

3. Małgorzata Mrowicka, "Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration—Neurodegenerative Disease," PubMed Central. ↩

4. Bénédicte M. J. Merle, "B Vitamins and Incidence of Advanced Age-Related Macular Degeneration: The Alienor Study," PubMed Central. ↩

5. Susanne Csader, "The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis," PubMed Central. ↩

6. Ronald P. Hobbs, "Nutrient Supplementation for Age-related Macular Degeneration, Cataract, and Dry Eye," PubMed Central. ↩

Research indicates that certain supplements may help manage symptoms of hyperhidrosis, although they are not primary treatments. Here are some potentially beneficial supplements:

1. Magnesium: Low magnesium levels have been associated with anxiety and depression in patients with primary hyperhidrosis¹. Supplementing with magnesium could help alleviate some of these symptoms.

2. Vitamin D: Deficiency in vitamin D has also been linked to increased symptoms of anxiety and depression in those with hyperhidrosis¹. Addressing vitamin D deficiency might improve overall well-being and potentially reduce sweating.

3. Cannabidiol (CBD): Some case studies suggest that CBD might reduce hyperhidrosis symptoms. This could be particularly beneficial for those experiencing anxiety-related hyperhidrosis².

These supplements might offer relief for some individuals but are not a replacement for conventional treatments like antiperspirants, medications, or procedures recommended by healthcare professionals.

Would you like help finding specific products containing these supplements?

Footnotes

1. Vildan Manav, "Evaluation of the serum magnesium and vitamin D levels and the risk of anxiety in primary hyperhidrosis," PubMed, 2021. ↩ ↩²

2. Rubens Pitliuk, "Unexpected improvement of hyperhidrosis with cannabidiol," PubMed Central, 2022. ↩